Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

renal · Mechanism Report

Does reduced kidney function raise circulating TMAO?

Reduced kidney function is associated with higher circulating TMAO because the kidneys are the main route of TMAO clearance.

PlausibleSeptember 30, 202610 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Kidney function is a major determinant of circulating TMAO because TMAO is cleared primarily through the kidneys, and reduced glomerular filtration is associated with higher TMAO levels.

laying out figure…
2 of 6 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim says TMAO is cleared mainly by the kidneys, so circulating levels rise when glomerular filtration declines. The graph frames this as a renal elimination effect, with kidney function acting as a major determinant of TMAO accumulation while other factors can also influence levels.

Verified conclusion

Kidney function is a major determinant of circulating trimethylamine N-oxide (TMAO), particularly in chronic kidney disease (CKD), because renal elimination is the dominant route and TMAO accumulates as glomerular filtration declines.

Clinical and clearance evidence

  • Human radiolabeled mass-balance data found ~94.5% of an administered TMA/TMAO dose recovered in urine within 24 hours, versus 4% in feces and <1% in breath, supporting predominant renal elimination.
  • In CKD, TMAO clearance closely approximated measured GFR (fractional excretion 105% ± 32%), and plasma TMAO rose as measured GFR fell.
  • A meta-analysis of 32 studies (42,062 participants) found a substantial inverse TMAO–GFR association (Fisher’s z −0.45, 95% CI −0.58 to −0.32). Advanced CKD was associated with 67.9 μmol/L higher TMAO than healthy controls (95% CI 52.7–83.2).
  • Individual CKD cohorts similarly reported an inverse TMAO–eGFR correlation (r = −0.48; p<0.001). Reported median TMAO concentrations were 7.9 μM in CKD versus 3.4 μM in controls, with still higher values in dialysis populations.

Mechanistic and clinical context

  • TMAO is largely excreted unchanged in urine. Available findings are compatible with glomerular filtration as the principal process; older clearance estimates also permit some tubular secretion, but its quantitative contribution remains uncertain.
  • Concentrations are not determined by kidney function alone. Egg and fish/seafood intake, fecal microbial genes for TMA production, and FMO3 genetic variation each associate with TMAO independently of eGFR in relevant cohorts.
  • Higher TMAO also predicted incident CKD in people with initially normal kidney function, but this longitudinal association does not establish that TMAO causes CKD.

Bottom line

  • The claim is strongly supported: reduced GFR impairs the principal elimination pathway for TMAO and is robustly associated with higher circulating concentrations, while diet, microbiome activity, and hepatic metabolism meaningfully modify individual levels.

References

  1. Trimethylamine N-Oxide in Relation to Cardiometabolic ... - PMC — pmc.ncbi.nlm.nih.gov ↗
  2. Elevation of Trimethylamine-N-Oxide in Chronic Kidney Disease — pmc.ncbi.nlm.nih.gov ↗
  3. Gut Microbiota-Derived Trimethylamine N-Oxide and Kidney Function: A Systematic Review and Meta-Analysis — pmc.ncbi.nlm.nih.gov ↗
  4. Gut Microbiota-Derived Trimethylamine N-Oxide and Kidney Function: A Systematic Review and Meta-Analysis - PubMed — pubmed.ncbi.nlm.nih.gov ↗
  5. The microbiome-derived metabolite trimethylamine N-oxide is ... — link.springer.com ↗
  6. Evidence of a causal and modifiable relationship between kidney function and circulating trimethylamine N -oxide — nature.com ↗
  7. Association of Circulating Trimethylamine N-Oxide and Its Dietary Determinants with the Risk of Kidney Graft Failure: Results of the TransplantLines Cohort Study — ncbi.nlm.nih.gov ↗
  8. Gut dysbiosis contributes to TMAO accumulation in CKD — academic.oup.com ↗
  9. Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients — journals.plos.org ↗
  10. The Gut Microbial Metabolite Trimethylamine N-oxide, Incident ... — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Unsupported8 sourcesDoes gadolinium in urine mainly indicate prior exposure rather than toxicity?→Plausible5 sourcesDoes most gadolinium-based contrast clear through the kidneys while small amounts persist in tissues later?→